1. Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials. (1st January 2019) Authors: Strober, B.E.; Gottlieb, A.B.; van de Kerkhof, P.C.M.; Puig, L.; Bachelez, H.; Chouela, E.; Imafuku, S.; Thaçi, D.; Tan, H.; Valdez, H.; Gupta, P.; Kaur, M.; Frajzyngier, V.; Wolk, R. Journal: British journal of dermatology Issue: Volume 180:Number 1(2019) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials3. (10th October 2018) Authors: Strober, B.E.; Gottlieb, A.B.; van de Kerkhof, P.C.M.; Puig, L.; Bachelez, H.; Chouela, E.; Imafuku, S.; Thaçi, D.; Tan, H.; Valdez, H.; Gupta, P.; Kaur, M.; Frajzyngier, V.; Wolk, R. Journal: British journal of dermatology Issue: Volume 180:Number 1(2019) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Tofacitinib benefit‐risk profile in chronic plaque psoriasis. (1st January 2019) Authors: Strober, B.E.; Gottlieb, A.B.; van de Kerkhof, P.C.M.; Puig, L.; Bachelez, H.; Chouela, E.; Imafuku, S.; Thaçi, D.; Tan, H.; Valdez, H.; Gupta, P.; Kaur, M.; Frajzyngier, V.; Wolk, R. Journal: British journal of dermatology Issue: Volume 180:Number 1(2019) Page Start: e19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Tofacitinib benefit‐risk profile in chronic plaque psoriasis. (2nd January 2019) Authors: Strober, B.E.; Gottlieb, A.B.; van de Kerkhof, P.C.M.; Puig, L.; Bachelez, H.; Chouela, E.; Imafuku, S.; Thaçi, D.; Tan, H.; Valdez, H.; Gupta, P.; Kaur, M.; Frajzyngier, V.; Wolk, R. Journal: British journal of dermatology Issue: Volume 180:Number 1(2019) Page Start: e19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 托法替布在慢性斑块型银屑病中的获益风险特征. (1st January 2019) Authors: Strober, B.E.; Gottlieb, A.B.; van de Kerkhof, P.C.M.; Puig, L.; Bachelez, H.; Chouela, E.; Imafuku, S.; Thaçi, D.; Tan, H.; Valdez, H.; Gupta, P.; Kaur, M.; Frajzyngier, V.; Wolk, R. Journal: British journal of dermatology Issue: Volume 180:Number 1(2019) Page Start: e32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 托法替布在慢性斑块型银屑病中的获益风险特征. (2nd January 2019) Authors: Strober, B.E.; Gottlieb, A.B.; van de Kerkhof, P.C.M.; Puig, L.; Bachelez, H.; Chouela, E.; Imafuku, S.; Thaçi, D.; Tan, H.; Valdez, H.; Gupta, P.; Kaur, M.; Frajzyngier, V.; Wolk, R. Journal: British journal of dermatology Issue: Volume 180:Number 1(2019) Page Start: e32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗